High Sensitivity Circulating Tumor-DNA Assays in Renal Cell Carcinoma–Are we there yet?

IF 2.3 3区医学 Q3 ONCOLOGY

Clinical genitourinary cancer Pub Date : 2024-10-10 DOI:10.1016/j.clgc.2024.102235

Fady Sidhom , Shefali Patel , Arpita Desai , Arnab Basu

{"title":"High Sensitivity Circulating Tumor-DNA Assays in Renal Cell Carcinoma–Are we there yet?","authors":"Fady Sidhom , Shefali Patel , Arpita Desai , Arnab Basu","doi":"10.1016/j.clgc.2024.102235","DOIUrl":null,"url":null,"abstract":"<div><div>As therapeutics in renal cell carcinoma (RCC) continues to advance with approval of novel treatments and recently, adjuvant therapy, the need for highly sensitive tests that go beyond traditional methods to measure disease is becoming more crucial. Tumor informed high sensitivity circulating tumor DNA (ctDNA) assays originally developed for detection of minimal residual disease (MRD) theoretically could be utilized for initial detection of occult disease but also potentially for risk and response assessment in the management of advanced RCC. There are concerns related to the sensitivity of ctDNA based assays in RCC. This article aims to summarize the available evidence for high sensitivity MRD assays in RCC. We included studies with both localized and metastatic stages of RCC. The studies show a varying sensitivity depending on disease settings but a high specificity (∼100%) regardless. Detectable ctDNA appeared to be a significant negative prognostic risk factor for subsequent progressive disease. ctDNA may provide significant lead time allowing physicians to adapt therapy. Several high sensitivity assays with novel analytic approaches are in development for solid tumors including RCC.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102235"},"PeriodicalIF":2.3000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324002052","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

As therapeutics in renal cell carcinoma (RCC) continues to advance with approval of novel treatments and recently, adjuvant therapy, the need for highly sensitive tests that go beyond traditional methods to measure disease is becoming more crucial. Tumor informed high sensitivity circulating tumor DNA (ctDNA) assays originally developed for detection of minimal residual disease (MRD) theoretically could be utilized for initial detection of occult disease but also potentially for risk and response assessment in the management of advanced RCC. There are concerns related to the sensitivity of ctDNA based assays in RCC. This article aims to summarize the available evidence for high sensitivity MRD assays in RCC. We included studies with both localized and metastatic stages of RCC. The studies show a varying sensitivity depending on disease settings but a high specificity (∼100%) regardless. Detectable ctDNA appeared to be a significant negative prognostic risk factor for subsequent progressive disease. ctDNA may provide significant lead time allowing physicians to adapt therapy. Several high sensitivity assays with novel analytic approaches are in development for solid tumors including RCC.

查看原文本刊更多论文

肾细胞癌中的高灵敏度循环肿瘤 DNA 检测--我们做到了吗？

随着肾细胞癌（RCC）治疗方法的不断进步，新型治疗方法和最近的辅助治疗方法获得批准，对超越传统方法测量疾病的高灵敏度检测的需求变得越来越重要。肿瘤信息高灵敏度循环肿瘤DNA（ctDNA）检测最初是为检测最小残留病（MRD）而开发的，理论上可用于隐匿性疾病的初步检测，也可用于晚期RCC管理中的风险和反应评估。基于ctDNA的检测方法在RCC中的灵敏度令人担忧。本文旨在总结RCC中高灵敏度MRD测定的现有证据。我们纳入了RCC局部和转移阶段的研究。这些研究显示，不同疾病的敏感性不同，但特异性都很高（100%）。可检测到的ctDNA似乎是后续进展性疾病的一个重要的负面预后风险因素。目前正在针对包括RCC在内的实体瘤开发几种具有新型分析方法的高灵敏度检测方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical genitourinary cancer 医学-泌尿学与肾脏学

CiteScore

5.20

自引率

6.20%

发文量

201

审稿时长

54 days

期刊介绍： Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.